-Down to Earth US actions jeopardise India's pro-poor patent laws that promote generic drugs production, says online global petition More than 75,000 people have requested Prime Minister Narendra Modi not to succumb to US pressure on Intellectual Property Rights (IP). With trade and intellectual property rights featuring prominently in the agenda of US president Barak Obama's India visit, civil society groups have expressed concern that talks on these issues are designed to make...

-The Telegraph New Delhi: India's patent regulating agency today rejected a US company's patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine. The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900...

-The Guardian Universal healthcare is often presented as an idealistic goal that remains out of reach for all but the richest nations. That's not the case, writes Amartya Sen. Look at what has been achieved in Rwanda, Thailand and Bangladesh Twenty-five hundred years ago, the young Gautama Buddha left his princely home, in the foothills of the Himalayas, in a state of agitation and agony. What was he so distressed about?...

-The Hindu New Delhi: While observing that the Court could not encroach into policy matters of the government, the Delhi High Court has dismissed a public interest writ petition seeking directions to the Centre to make available generic medicines and medical treatment to the public at large at a reasonable cost. A Division Bench comprising Chief Justice G. Rohini and Justice R.S. Endlaw had earlier this week said that the Centre and...

-Vikalp Once again, India is under pressure from the US to revise its patent law. Anyone familiar with the activities of the United States Trade Representatives (USTR) would know that this is nothing new. It has been among the USTR's primary mandates to use trade restrictions in order to persuade (to put it mildly) countries to strengthen their IPR laws. There is, however, a qualitative difference between the actions it has...